MENU

Market Realities

The market can stay irrational longer than you can stay solvent

Comments

Mimie Acosta

In late 2020, I bought shares of an overlooked pharmaceutical company at $1500, aiming for a 4:1 risk-reward ratio. With a stop-loss at $1300 and a target of $2300, positive clinical trials pushed the stock to $2500. I exited at $23, securing a substantial profit and learning the importance of diligent research and a well-thought-out plan

Leave a Reply

Your email address will not be published. Required fields are marked *